Demian Mousad, MD
Interventional Pain Medicine · Worcester, MANPI 1336106574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $663 and has fallen 94.6% since, to $36 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in MA, where the typical reported total is $4,278.
Across 53 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fidia Pharma USA Inc.$160
- Boston Scientific$130
- Lilly USA, LLC$102
- Teva Pharmaceuticals USA, Inc.$71
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$69
- Bioventus LLC$56
- plus $345 from 13 others
What the payments were for
- Food & beverage$932100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fidia Pharma USA Inc. | 8 | $160 |
| Boston Scientific | 7 | $130 |
| Lilly USA, LLC | 6 | $102 |
| Teva Pharmaceuticals USA, Inc. | 5 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Bioventus LLC | 2 | $56 |
| Scilex Pharmaceuticals Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $44 |
| Pfizer | 3 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Biodelivery Sciences International, Inc. | 2 | $25 |
| Redhill Biopharma Inc. | 1 | $22 |
| Zimmer Biomet | 1 | $21 |
| Amgen | 1 | $21 |
| Tonix Medicines, Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $16 |
| Shionogi Inc | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
How this compares
$932 in reported general payments places this provider in the 20th percentile of 22 interventional pain medicine providers in Massachusetts.
See all interventional pain medicine providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 14 | $24,284 |
| BelbucaBuprenorphine Hcl | 32 | $14,427 |
| Buprenorphine | 51 | $10,304 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $4,898 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 212 | $3,577 |
| Lidocaine | 16 | $3,347 |
| Gabapentin | 315 | $3,213 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 164 | $2,734 |
| Diclofenac Sodium | 30 | $1,946 |
| Pregabalin | 133 | $1,818 |
| Baclofen | 209 | $1,712 |
| Naloxone Hcl | 22 | $1,451 |
| Oxycodone Hcl | 140 | $1,358 |
| Duloxetine Hcl | 68 | $784 |
| Celecoxib | 67 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $37 | $24,28414 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $12 | $14,42732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 22 interventional pain medicine providers in Massachusetts.
Other interventional pain medicine in Worcester
- Warren Mackie-JenkinsBoston$65K
- Mark JonesBoston$48K
- Frederic GergesBoston$21K
- David DibenedettoWaltham$17K
- Anil KumarStoneham$8K
- Omar QureshiFitchburg$7K
- Rami RustumMethuen$6K
- Janet PearlFramingham$5K
- Yuri KhibkinHolyoke$5K
- Erica BialBurlington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.